O 1 P E 103 2004 65

Modified Form PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

		Sheet	<u> </u>	Of	2
Atty. Docket No.		Serial No.			
A -6	665B	Į.	09/84	3.221	
Applicant					
Ko	stenuik, et al.				
Filing Date		Group			-
An	ril 26. 2001		1647		

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
(30)	A1	5,693,616	02 Dec 1997	Krstenansky et al.			
	A2	5,807,823	15 Sep 1998	Krstenansky et al.			
V	A3	5,874,086	23 Feb 1999	Krstenansky et al.			
(30)	A4	6,417,333 B1	09 Jul 2002	Bringhurst et al.			
	A 5						
	A 6				· · · · · · · · · · · · · · · · · · ·		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANS	ATION
					CLASS	YES	NO
B1						i	
B 2							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

9	C1	Baumann et al., Response of Cortical Bone to Antiresorptive Agents and Parathyroid Hormone in Aged Ovariectomized Rats. BONE, 16(6): 247-253. (Feb 1995).
	C2	Berning et al., Tibolone and its effects on bone: a review. CLIMACTERIC, 4(2):120-136. (June 2001).
	C3	Crandall, C., Parathyroid Hormone for Treatment of Osteoporosis. ARCHIVES OF INTERNAL MEDICINE, 162: 2297-2309. (11 Nov 2002).
	C4	Hodsman, A. B. et al., Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. BONE AND MINERAL., 9(2): 137-152. (May 1990)
	C5	Hofbauer, L. C. et al., Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. ENDOCRINOLOGY, 140(10): 4382-4389. (Oct 1999)
	C6	Kostenuik, P. J. et al., OPG and PTH(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. ENDOCRINOLOGY, 142(10): 4295-4304. (Oct 2001)
	C7	Li, M. et al., Parathyroid Hormone Monotherapy and cotherapy with Antiresorptive Agents Restore Vertebral Bone Mass and Strength in Aged Ovariectomized Rates. BONE, 16(6): 629-635. (Jun 1995)
	C8	Morley, P. et al., Parathyroid Hormone: An Anabolic Treatment for Osteoporosis. CURRENT PHARMACEUTICAL DESIGN, 7(8): 671-687. (May 2001).
EXAMINER:	C9	Reeve, J. et al., Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J. BONE MINR. METAB., 19(2): 102-114. (09 March 2001).
EXAMINEH!		Pate Considered:

EXAMINER:

Date Considered:

2 17/2004

EXAMINER: Initial light property whether or not of philosope in conformance with MPER 500. Drow the through pitaline if each property and an application for the conformance with MPER 500. Drow the through pitaline if each property and application of the conformance and the conformance

EXAMINER: Initial Include copy of this form with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant



EXAMINER'S INITIALS		OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)
600	C10	Rosen et al., CLINICAL REVIEW 123: HOT TOPIC Anabolic Therapy for Osteoporosis. THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 86(3): 957-964, (Mar 2001).
	C11	Tanizawa et al., Effects of human PTH (1-34) and bisphosphonate on the osteopenic rat model.
(D)	CII	TOXICOLOGY LETTERS. 102-103: 399-403, (Dec 1998).
CON	C12	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	C18	
	C19	
	C20	
	C21	
	C22	
	C23	
	C24	
	C25	
	C26	
	C27	·
	C28	·
	C29	
	C30	
	C31	
EXAMINER:		Date Considered: 2/7/2004
EXAMINER: Initial is communication to a	citation of pplicant.	certifiered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next